IHE vs OZEM

IHEBiShares U.S. Pharmaceuticals ETF

OZEMCRoundhill GLP-1 & Weight Loss ETF

In short

IHE The domestic purist of pharma funds: about 60 US drug and vaccine makers, weighted by size, no foreign names riding along. Running since 2006, it is the plain cap-weighted take on Big Pharma.

OZEM The whole weight-loss trade in one ticker: roughly 30 stocks covering the drugmakers behind GLP-1 treatments plus the companies expected to benefit as use widens. Broad pharma funds bury this theme. OZEM is built entirely around it.

Stated mandate

IHE The fund seeks to track an index of U.S. companies in the pharmaceuticals sector, giving investors targeted exposure to domestic drug manufacturers and vaccine producers.

OZEM The Fund seeks capital appreciation by providing exposure to companies developing pharmaceutical drugs for weight loss and anti-obesity, including GLP-1 treatments, as well as companies expected to benefit from their wider use.

Why people hold it

• IHE Costs 0.37% a year against a 0.57% median for pharma funds, landing within a basis point or two of the cheapest options in the group.
• Tracks the Dow Jones U.S. Select Pharmaceuticals Index: domestic drug and vaccine makers only, not the US-listed foreign pharma that PPH's index also picks up.vaneck.com
• Trading since 2006 under the iShares banner, now a billion-dollar-plus fund with moderate daily volume and quarterly distributions.
• Sits in the upper half of its pharma peer group on our review, one of the sturdier implementations of a simple, cheap, index-following mandate.

• OZEM The mandate is explicit: companies developing weight-loss and anti-obesity drugs, including GLP-1s, plus firms expected to benefit from wider use. No hedging into general pharma.
• A roughly 30-stock lineup means the theme actually drives the fund, rather than sitting as a small sleeve inside a diversified pharma basket.
• At 0.59%, the fee sits in the same neighborhood as established pharma funds like PJP (0.57%) and FTXH (0.60%), despite the narrower, more specialized mandate.

Worth knowing

• IHE Cap weighting across about 60 names puts the largest US drug makers in the driver's seat; XPH uses modified equal weight to spread dollars across large, mid and small caps.ssga.com
• Pharma only. No biotech, devices or insurers, and the fund is non-diversified, making it a narrow slice of health care.ishares.com
• The 0.37% fee undercuts the category median but not the floor: XPH at 0.35% and PPH at 0.36% shade it slightly.

• OZEM Broad pharma alternatives are cheaper: XPH at 0.35% and PPH at 0.36%. The theme focus here carries a price.
• Thinly traded with a modest asset base, so spreads can be wide. Limit orders are the standard tool for funds in this range.
• Launched in 2024, so the history is short, and a 30-stock single-theme basket swings on trial results and regulatory news at a handful of companies.

Full IHE profile⁠

Full OZEM profile⁠